



REITERATION ON THE USE OF RESTRICTED ANTIMICROBIALS IN PHILHEALTH-ACCREDITED HEALTH CARE INSTITUTIONS IN ACCORDANCE WITH THE REQUIREMENTS OF THE ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM (ARSP)

Pursuant to PhilHealth Circular No. 2018-0009, the transition period for ARSP accreditation has ended last June 30, 2019. Starting this July, in order to use restricted antimicrobials, PhilHealth accredited hospitals have the following options:

OPTIONS		DOCUMENTARY REQUIREMENTS
A	Be accredited by Research Institute for Tropical Medicine (RITM) as ARSP laboratory and have either of the following: <ul style="list-style-type: none"> ▪ DOH Antimicrobial Stewardship (AMS)-trained chairperson of the Infectious Control Committee (ICC) or AMS Committee; ▪ Board-certified infectious disease specialist (IDS) who shall authorize the use of restricted antimicrobials per patient. 	Either of the following: <ul style="list-style-type: none"> ▪ Composition of the ICC or AMS Committee and Certificate of AMS training of the ICC or AMS chairperson; ▪ Appointment for a board-certified IDS who shall authorize the use of restricted antimicrobials per patient
B	If not yet ARSP accredited, outsource with an ARSP-accredited laboratory thru a Memorandum of Agreement (MOA)	<ul style="list-style-type: none"> ▪ MOA with an ARSP-accredited laboratory

The applicable documentary requirements shall be submitted by the health care providers to their respective PhilHealth Regional Office (PRO).

For additional information on ARSP, please refer to PC 2018-0009 and the corresponding “Tamang Sagot” found on our website at www.philhealth.gov.ph

Further inquiries may be referred to our Corporate Action Center at (02) 441 7442 or through actioncenter@philhealth.gov.ph


BGEN. RICARDO C. MORALES, AFP (RET) FICD
 President and Chief Executive Officer